Literature DB >> 18081556

The anti-ghrelin Spiegelmer NOX-B11-3 blocks ghrelin- but not fasting-induced neuronal activation in the hypothalamic arcuate nucleus.

C Becskei1, K U Bilik, S Klussmann, F Jarosch, T A Lutz, T Riediger.   

Abstract

The hypothalamic arcuate nucleus (Arc) is the presumed target site for the orexigenic hormone ghrelin, which is secreted from the stomach during fasting. Ghrelin directly activates Arc neurones. Similar to exogenous ghrelin, overnight food deprivation also induces c-Fos expression in the Arc of mice. In the present study, we tested the role of endogenous ghrelin in the fasting-induced c-Fos expression in the Arc of mice. We used NOX-B11-3, the latest generation of the recently developed ghrelin-binding compounds, so-called RNA Spiegelmers (SPM) to block endogenous ghrelin action during food deprivation. The specificity and potency of this compound was also tested in electrophysiological and immunohistological experiments. In electrophysiological in vitro single cell recordings, NOX-B11-3 effectively blocked the excitatory effect of ghrelin in the medial Arc (ArcM) of rats whereas the biologically inactive control SPM had no effect. Furthermore, NOX-B11-3 (15 mg/kg i.p.) potently suppressed ghrelin-induced (25 microg/kg s.c., 12 h after SPM injection) c-Fos expression in the Arc. However, when injected at the beginning of a 14-h fasting period, the same dose of NOX-B11-3 had no effect on the c-Fos expression in the Arc of mice. These results demonstrate that NOX-B11-3 is a long-acting compound, which effectively blocks the effect of exogenous ghrelin on neuronal activity in the Arc under in vitro and in vivo conditions. Furthermore, increased ghrelin signalling does not appear to be a necessary factor for the activation of Arc neurones during food deprivation or other fasting-related signals might have masked or compensated for the loss of the ghrelin effect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18081556     DOI: 10.1111/j.1365-2826.2007.01619.x

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  13 in total

1.  Oligoclonal antibody targeting ghrelin increases energy expenditure and reduces food intake in fasted mice.

Authors:  Joseph S Zakhari; Eric P Zorrilla; Bin Zhou; Alexander V Mayorov; Kim D Janda
Journal:  Mol Pharm       Date:  2011-12-23       Impact factor: 4.939

2.  Corticotropin-releasing factor-overexpressing mice exhibit reduced neuronal activation in the arcuate nucleus and food intake in response to fasting.

Authors:  Andreas Stengel; Miriam Goebel; Mulugeta Million; Mary P Stenzel-Poore; Peter Kobelt; Hubert Mönnikes; Yvette Taché; Lixin Wang
Journal:  Endocrinology       Date:  2008-09-11       Impact factor: 4.736

Review 3.  New targets to treat obesity and the metabolic syndrome.

Authors:  Kathleen A Martin; Mitra V Mani; Arya Mani
Journal:  Eur J Pharmacol       Date:  2015-05-19       Impact factor: 4.432

4.  Anti-ghrelin Spiegelmer inhibits exogenous ghrelin-induced increases in food intake, hoarding, and neural activation, but not food deprivation-induced increases.

Authors:  Brett J W Teubner; Timothy J Bartness
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-06-26       Impact factor: 3.619

Review 5.  Regulation of appetite to treat obesity.

Authors:  Gilbert W Kim; Jieru E Lin; Michael A Valentino; Francheska Colon-Gonzalez; Scott A Waldman
Journal:  Expert Rev Clin Pharmacol       Date:  2011-03       Impact factor: 5.045

Review 6.  Role of ghrelin in the pathophysiology of eating disorders: implications for pharmacotherapy.

Authors:  Sebastian Cardona Cano; Myrte Merkestein; Karolina P Skibicka; Suzanne L Dickson; Roger A H Adan
Journal:  CNS Drugs       Date:  2012-04-01       Impact factor: 5.749

7.  Ghrelin in diabetes and metabolic syndrome.

Authors:  Leena Pulkkinen; Olavi Ukkola; Marjukka Kolehmainen; Matti Uusitupa
Journal:  Int J Pept       Date:  2010-04-27

Review 8.  Pharmacological Modulation of Ghrelin to Induce Weight Loss: Successes and Challenges.

Authors:  Martha A Schalla; Andreas Stengel
Journal:  Curr Diab Rep       Date:  2019-09-10       Impact factor: 4.810

9.  The hungry stomach: physiology, disease, and drug development opportunities.

Authors:  Gareth J Sanger; Per M Hellström; Erik Näslund
Journal:  Front Pharmacol       Date:  2011-02-18       Impact factor: 5.810

10.  Recent advances in potential clinical application of ghrelin in obesity.

Authors:  Christine Delporte
Journal:  J Obes       Date:  2012-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.